Positron emission tomography of 64Cu-DOTA-rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL

Molecular Imaging and Biology

Volumn 14, Issue 5, 2012, Pages 608-616

  Natarajan, Arutselvan ^a   Gowrishankar, Gayatri ^a   Nielsen, Carsten H ^a   Wang, Sen ^a   Iagaru, Andrei ^a   Goris, Michael L ^b   Gambhir, Sanjiv Sam ^b,c  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Stanford University   (United States)

Author keywords

64Cu rituximab; ImmunoPET; Radioimmuno imaging

Indexed keywords

CD20 ANTIGEN; COPPER TETRAXETAN RITUXIMAB CU 64; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CHELATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; QUALITY CONTROL; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RADIOACTIVITY; RADIOISOTOPE DISTRIBUTION; TRANSGENIC MOUSE;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COPPER RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, RADIATION; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; ISOTOPE LABELING; LYMPHOMA, NON-HODGKIN; MALE; MASS SPECTROMETRY; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TRANSLATIONAL MEDICAL RESEARCH;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 84870454253     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-011-0537-8     Document Type: Article

References (42)

1. Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354:496-507
2. Larson SM (1985) Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J Nucl Med 26:538-545
3. Wu AM, Yazaki PJ, Tsai S, Nguyen K, Anderson AL, McCarthy DW et al (2000) High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A 97:8495-8500
4. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR et al (1978) Use of radio-labeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 298:1384-1388
5. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM et al (1998) Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 77:1405-1412
6. Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 359:613-626
7. Dearling JL, Voss SD, Dunning P, Snay E, Fahey F, Smith SV, et al (2011) Imaging cancer using PET - the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody. Nucl Med Biol 38: 29-38
8. Forrer F, Chen J, Fani M, Powell P, Lohri A, Muller-Brand J et al (2009) In vitro characterization of (177)Lu-radiolabelled chimeric anti- CD20 monoclonal antibody and a preliminary dosimetry study. Eur J Nucl Med Mol Imaging 36:1443-1452
9. Zhou X, Hu W, Qin X (2008) The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13:954-966
10. Glennie MJ, French RR, Cragg MS, Taylor RP (2007) Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 44:3823- 3837
11. Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, Brechbiel MW (2000) Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol 27:93-100
12. Chappell LL, Ma D, Milenic DE, Garmestani K, Venditto V, Beitzel MP et al (2003) Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane- N, N′, N″, N″′- tetraacetic acid for radiolabeling proteins. Nucl Med Biol 30:581-595
13. Li J, Zheng H, Trent J, Bates P, Ng CK (2009) Evaluation of 64Cu- DOTA-AS1411 as a PET tracer for lung cancer imaging. J Nucl Med Meet (Abstracts) 50:1915
14. Li L, Bading J, Yazaki PJ, Ahuja AH, Crow D, Colcher D et al (2007) A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging Of CEA-positive tumors with whole antibodies. Bioconjugate Chem 19:89-96
15. Lu SX, Takach EJ, Solomon M, Zhu Q, Law SJ, Hsieh FY (2005) Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy. J Pharm Sci 94:788-797
16. Grunberg J, Novak-Hofer I, Honer M, Zimmermann K, Knogler K, Blauenstein P et al (2005) In vivo evaluation of 177Lu- and 67/64Culabeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors. Clin Cancer Res 11:5112-5120
17. Zimmermann K, Grünberg J, Honer M, Ametamey S, August Schubiger P, Novak-Hofer I (2003) Targeting of renal carcinoma with 67/64Culabeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. Nucl Med Biol 30:417-427
18. Novak-Hofer I, Zimmermann K, Maecke HR, Amstutz HP, Carrel F, Schubiger PA (1997) Tumor uptake and metabolism of copper-67- labeled monoclonal antibody chCE7 in nude mice bearing neuroblastoma xenografts. J Nucl Med 38:536-544
19. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72:77-89
20. Saludes JP, Natarajan A, DeNardo SJ, Gervay-Hague J (2010) The remarkable stability of chimeric, sialic acid-derived alpha/delta-peptides in human blood plasma. Chem Biol Drug Des 75:455-460
21. Adams GP, DeNardo SJ, Deshpande SV, DeNardo GL, Meares CF, McCall MJ et al (1989) Effect of mass of 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice. Cancer Res 49:1707-1711
22. Schipper ML, Cheng Z, Lee SW, Bentolila LA, Iyer G, Rao J et al (2007) microPET-based biodistribution of quantum dots in living mice. J Nucl Med 48:1511-1518
23. Loening AM, Gambhir SS (2003) AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2:131-137
24. Kirschner AS, Ice RD, Beierwaltes WH (1973) Radiation dosimetry of 131I-19-iodocholesterol. J Nucl Med 14:713-717
25. Stabin MG, Siegel JA (2003) Physical models and dose factors for use in internal dose assessment. Heal Phys 85:294-310
26. Dunphy MP, Lewis JS (2009) Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med 50(Suppl 1):106S-121S
27. Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J et al (2009) Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 50:974-981
28. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR et al (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87:586-592
29. Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P (2005) The role of imaging with 111In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a zevalin imaging registry. J Nucl Med 46:1812-1818
30. Jalilian AR, Mirsadeghi L, Yari-Kamrani Y, Rowshanfarzad P, Kamali-Dehghan M, Sabet M (2007) Development of [Cu-64]- DOTA-anti-CD20 for targeted therapy. J Radioanal Nucl Chem 274:563-568
31. Chan C, Scollard D, McLarty K, Smith S, Reilly R (2011) A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. EJNMMI Res 1:15
32. Dixit R, Boelsterli UA (2007) Healthy animals and animal models of human disease(s) in safety assessment of human pharmaceuticals, including therapeutic antibodies. Drug Discov Today 12:336- 342
33. Tsukamoto N, Kojima M, Hasegawa M, Oriuchi N, Matsushima T, Yokohama A et al (2007) The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer 110:652-659
34. (1996) Radiological protection and safety in medicine. Annals of the ICRP 26: 1-31
35. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833
36. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM (2006) Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 47:793-796
37. Olafsen T, Sirk SJ, Betting DJ, Kenanova VE, Bauer KB, Ladno W et al (2010) ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel 23:243-249
38. Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F (2006) Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer 107:175-183
39. Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM (2008) Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas. J Immunol 181:4131-4140
40. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L et al (2005) Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 174:817-826
41. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ (2007) Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 179:3351-3361
42. Mease PJ (2008) B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol 35:1245- 1255